Report Id: SNS/HC/2565 | July 2022 | Region: Global | 125 Pages
Report Scope & overview:
Heart Failure POC & LOC Devices Market Size was valued at USD 71.9 million in 2021, and expected to reach USD 210.8 million by 2028, and grow at a CAGR of 16.6% over the forecast period 2022-2028.
In contrast to Lab-On-Chip (LOC) devices, which combine many laboratory activities on a single circuit to allow automation and high throughput screening, Point-of-Care (POC) devices are used to obtain diagnostic data close to the patients. Heart failure can be diagnosed using POC assays, and POC and central lab testing can both be done using LOC device technology. Point-of-care testing finds heart markers and other time-critical indications to address the challenges of health inequities. The global market for POC & LOC devices for heart failure is being driven by reasons including a growth in cardiovascular diseases (CVDs), an increase in the elderly population, and increased R&D for POC & LOC devices. Unfavorable reimbursement practices, however, could impede market expansion during the projection period.
More cardiovascular disorders
more R&D is being done for POC and LOC devices
Increase in the elderly population
Ambiguous payment procedures
Increased investment in the study of cardiovascular and heart diseases
Creation of more recent, suitable POC and LOC heart failure biomarkers
Lack of knowledge of regulatory requirements
IMPACT OF COVID-19
People all around the world have been impacted by the current COVID-19 pandemic, which has also forced the closure of operational facilities globally. Unexpected difficulties arose for the healthcare industry during the shutdown. Medical device and other healthcare product manufacture ceased as the manufacturing facilities were shut down. Additionally, the supply network for medical supplies was broken, which increased manufacturing stockpiling.
For the businesses in the heart failure POC & LOC devices industry, this COVID-19 pandemic is also presenting prospects. Many COVID-19 survivors will be at risk for developing pulmonary hypertension, chronic right heart failure, and diastolic dysfunction, particularly those who have recovered from serious illness with considerable hypoxemic respiratory failure and thromboembolic repercussions. Additionally, the need for POC & LOC devices for heart failure is anticipated to rise because to the growing demand for electronic health records, telehealth, and constraints limiting patients avoid physically visiting hospitals and testing labs.
By Test Type
Clinicians can benefit greatly from knowledge of the pathways involved in heart failure (HF) provided by circulating protein biomarkers. Thanks to developments in proteomics, researchers may now simultaneously evaluate a large number of proteins with great sensitivity and selectivity to find low-abundance proteins. C-reactive protein (CRP), troponin, and B-type natriuretic peptide (BNP) are a few protein indicators that POC devices can identify as heart failure. Due to the rising need for precise and effective protein biomarkers like troponin for the diagnosis and treatment of heart failure, proteomic testing retained the majority of the market share in this sector.
Small organic compounds that are present in several metabolic processes are the subject of metabolomics research. Metabolomic profiles created through serum and breath analysis are available for patients with systolic heart failure, and they can be utilised clinically to diagnose and predict the condition.
Genomic testing makes it possible to diagnose heart failure by determining whether the patient has a gene mutation or genetic flaw that could result in an inherited heart condition (IHC). Laboratory-based detection methods like the Polymerase Chain Reaction (PCR) are frequently inaccessible in resource-constrained settings due to a lack of sophisticated infrastructures, dependable electricity, and skilled operators. Conversely, POCT enables on-the-spot detections in these circumstances.
Microfluidics is well suited to modelling the circulatory system due to its inherent properties. Fluid manipulation and detection can be done in one device with a minimal number of samples by adding microfluidics into POC testing. Due to many benefits such low reagent demand, minimum sample size, and high throughput, microfluidics had the greatest share in the technology segment. Additionally, POC and LOC devices based on microfluidics aid in the identification and measurement of heart failure-related biomarkers, which are crucial for the diagnosis of heart failure.
By End User
Point-of-care testing is widely used in hospitals and clinics. POCT helps patients to go home sooner since it produces results more quickly than central laboratory testing. Clinician decision-making is aided by this. Due to all of these characteristics, POC &LOC devices are significantly more beneficial for clinics to effectively provide outpatient care and treat a wider patient pool in a short amount of time.
As patients and caregivers favor less invasive techniques for health monitoring, the usage of POC and LOC devices for home use is also rising. Additionally, the convenience of testing at home as opposed to going to medical facilities supports the expansion of this market.
Some of the major key players are as follows: Abaxis, Inc., bioMérieux S.A, Danaher, Abbott, Siemens Healthineers, Hoffmann-La Roche Ltd., Instrumentation Laboratory Company, Jant Pharmacal Corporation, Quidel Corporation, and Trinity Biotech.
By Test Type
By End User
Due to the large market players in North America who are fostering significant organic revenue growth in the worldwide heart failure POC & LOC devices market, the region led the revenue share. However, the demand for diagnostic services is still growing in Asian nations. This is because chronic conditions including myocardial infarction, acute coronary syndrome, and heart ischemia are now being prioritized over infectious infections, which has caused a shift in focus. Aside from that, Asian nations are increasingly in demand as locations for global diagnostic companies to expand their operations due to rising medical practice standards and the creation of cutting-edge infrastructure.
Rest of Europe
Rest of Asia-Pacific
The Middle East & Africa
Rest of Middle East & Africa
Rest of Latin America
|Market Size in 2021||US$ 71.9 Billion|
|Market Size by 2028||US$ 210.8 Billion|
|CAGR||CAGR of 16.6% From 2022 to 2028|
|Report Scope & Coverage||Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook|
|Key Segments||• By Test Type (Proteomic Testing, Metabolomic Testing, Genomic Testing)
• By Technology (Microfluidics, Array-based Systems)
• By End User (Hospitals &Clinics, Homecare, Specialty Centers)
|Regional Analysis/Coverage||North America (USA, Canada, Mexico), Europe
(Germany, UK, France, Italy, Spain, Netherlands,
Rest of Europe), Asia-Pacific (Japan, South Korea,
China, India, Australia, Rest of Asia-Pacific), The
Middle East & Africa (Israel, UAE, South Africa,
Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America)
|Company Profiles||Abaxis, Inc., bioMérieux S.A, Danaher, Abbott, Siemens Healthineers, Hoffmann-La Roche Ltd., Instrumentation Laboratory Company, Jant Pharmacal Corporation, Quidel Corporation, and Trinity Biotech.|
|Key Drivers||• More cardiovascular disorders
• more R&D is being done for POC and LOC device
• Increase in the elderly population
|RESTRAINTS||• Ambiguous payment procedures|
Frequently Asked Questions (FAQ) :
Ans. Heart Failure POC & LOC Devices market is expected to grow at a CAGR of 16.6%.
Ans Increased investment in the study of cardiovascular and heart diseases, Creation of more recent, suitable POC and LOC heart failure biomarkers are the opportunities of the market.
Ans. Heart Failure POC & LOC Devices Market is divided into three segments and they are By Test Type, By Technology, and By End User
Ans. Due to the large market players in North America who are fostering significant organic revenue growth in the worldwide heart failure POC & LOC devices market, the region led the revenue share
Ans. Proteomic Testing, Metabolomic Testing, and Genomic Testing are sub segments of by test type of the Heart Failure POC & LOC Devices Market.
Table of Content:
1.1 Market Definition
1.3 Research Assumptions
2. Research Methodology
3. Market Dynamics
4. Impact Analysis
4.1 COVID 19 Impact Analysis
4.2 Impact of Ukraine ware
5. Value Chain Analysis
6. Porter’s 5 forces model
7. PEST Analysis
8. Heart Failure POC & LOC Devices Market Segmentation, By Test Type
8.1 Proteomic Testing
8.2 Metabolomic Testing
8.3 Genomic Testing
9. Heart Failure POC & LOC Devices Market Segmentation, By Technology
9.2 Array-based Systems
10. Heart Failure POC & LOC Devices Market Segmentation, By End User
10.1 Hospitals &Clinics
10.3 Specialty Centers
11. Regional Analysis
11.2 North America
11.3.6 The Netherlands
11.3.7 Rest of Europe
11.4.2 South Korea
11.4.6 Rest of Asia-Pacific
11.5 The Middle East & Africa
11.5.3 South Africa
11.6 Latin America
11.6.3 Rest of Latin America
12.1 Abaxis, Inc.
12.1.2 Products/ Services Offered
12.1.3 SWOT Analysis
12.1.4 The SNS view
12.2 bioMérieux S.A
12.5 Siemens Healthineers
12.6 Hoffmann-La Roche Ltd.
12.7 Instrumentation Laboratory Company
12.8 Jant Pharmacal Corporation
12.9 Quidel Corporation
12.10 Trinity Biotech
13.1 Competitive Benchmark
13.2 Market Share analysis
13.3 Recent Developments
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of a good and accurate research report and selecting the best methodology to complete the research is the toughest part. Since the research reports, we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach a stage wherein we can provide our clients best and most accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brainstorming sessions to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research as the name suggests is a research process wherein, we collect data through readily available information. In this process, we use various paid and unpaid databases to which our team has access and gather data through the same. This includes examining listed companies’ annual reports, Journals, SEC filling, etc. Apart from this, our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various universities as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content-specific facts that can be sued to solve specific problems. Since the collected data is fresh and first-hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply sides of the industry to make sure we land an accurate judgment and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses, and observation of on-field participants. The below-mentioned chart should give a better understanding of part 1 of the primary interview.
Part 2: In this part of the primary research the data collected via secondary research and part 1 of the primary research is validated with the interviews with individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence center, our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real-time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but is not limited to getting rid of the many typos, duplication of numbers, or missing any important information. The people involved in this process include technical content writers, research heads, and graphics people. Once this process is completed the title gets uploaded on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.